U.S. senators asked five drugmakers to explain increases in the price of naloxone, a drug that is used to reverse the effects of opioids, according to a Bloomberg article. The senators also want to know what the companies are doing to preserve access to the drug, which hospitals have said they’ve had trouble obtaining.
Senators Susan Collins, a Maine Republican, and Claire McCaskill, a Missouri Democrat, wrote to Pfizer Inc., Mylan NV, Amphastar Pharmaceuticals Inc., Adapt Pharma Inc. and Kaleo Inc., asking them to explain price changes for naloxone, the story said. They cited a report in Politico that at least one version of the drug has risen in price by as much as 17-fold in the last two years.
Read the Bloomberg article